['human immunodeficiency virus', 'dolutegravir', 'monotherapy', 'treatment efficacy']
['dolutegravir']

        Inclusion Criteria:

          -  HIV-1 infection;

          -  Patient included in the Swiss HIV Cohort Study (SHCS);

          -  ≥ 18 years of age;

          -  Virologically suppressed for at least 24 months on first line triple ART (changes for
             toxicity permitted) with at least 4 HIV-1 RNA measurements in plasma <50 copies/ml;

          -  No history of previous failure on ART;

          -  No documented antiretroviral drugs resistance;

          -  No co-infection with Hepatitis B or C virus;

          -  Effective contraception in women;

          -  Willing to provide CSF and semen samples;

          -  Written informed consent

        Exclusion Criteria:

          -  HIV-2 infection;

          -  Renal dysfunction (creatinine clearance <50ml/min);

          -  aspartate transaminase or alanine aminotransferase >5x upper limit normal;

          -  Concomitant use of carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's
             wort, rifampicin or metformin;

          -  Previous AIDS defining conditions or active malignancy in the past five years;

          -  Positive HIV viral load in CSF at baseline;

          -  Known or suspected non-compliance;

          -  Women who are pregnant or breastfeeding.
      